Overview

A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment

Status:
RECRUITING
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the performance of biomarkers and their responsiveness to standard-of-care treatments (Vevye or Xiidra), in participants with dry eye disease (DED) compared to healthy volunteers (control participants).
Phase:
PHASE4
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
lifitegrast